Serving To Educate Primary Care Clinicians On Metabolic Issues
Home
Subscribe
Feedback
Contact Us
Evidence Based Medicine
Medical Education
Metabolic Diseases
About Us
PCMG CME
PCMG Non-CME
Resources
Needs Survey
Commentaries
Survey
VMS Webinar Post Survey
I am a(n)…
[ Required ]
Select...
MD/DO
NP/RN
PA
Other
How many years have you been in practice?
[ Required ]
Select...
1-5
6-10
11-15
16-20
Over 20
What is your practice setting?
[ Required ]
Select...
Solo Practice
Group Practice
Hospital
Clinic
Academic
Other
Number of patients seen per month with menopause
[ Required ]
Select...
1-10
11-20
21-30
31-40
41-50
Over 50
Please rate the following:
Degree to which your educational expectations were met
[ Required ]
Select...
Excellent
Above Average
Average
Fair
Poor
Relevance to your practice
[ Required ]
Select...
Excellent
Above Average
Average
Fair
Poor
Effective faculty presenter
[ Required ]
Select...
Excellent
Above Average
Average
Fair
Poor
Overall Presentation
[ Required ]
Select...
Excellent
Above Average
Average
Fair
Poor
Please rate the degree to which Learning Objectives were met.
Describe the burden and undertreatment of menopause-associated VMS and the impact of these symptoms on patients’ quality of life.
[ Required ]
Select...
Completely
Mostly
Somewhat
Not at all
Incorporate clinical safety and efficacy data for new and emerging therapies into treatment regimens for VMS.
[ Required ]
Select...
Completely
Mostly
Somewhat
Not at all
Develop patient-specific therapeutic regimens for patients with VMS, including hormonal and non-hormonal therapies as appropriate.
[ Required ]
Select...
Completely
Mostly
Somewhat
Not at all
Agree or Disagree?
The presentation was fair and balanced, free of commercial bias.
[ Required ]
Select...
YES
NO
I feel more competent as a result of the presentation.
[ Required ]
Select...
YES
NO
The presentation was scientifically rigorous.
[ Required ]
Select...
YES
NO
This activity will help the healthcare team improve patient outcomes in my practice setting.
[ Required ]
Select...
Strongly Agree
Agree
Unsure
Disagree
Strongly Disagree
Will you change your practice behaviors as a result of the presentation?
[ Required ]
Select...
Absolutely
Probably
Unsure
Unlikely
No
What will you change?
[ Required ]
Proactively identify patients with VMS symptoms
Design treatment regimens for menopause-associated VMS based on patients' needs
Incorporate the most recent clinical evidence for menopause-associated VMS treatments
I will use this knowledge to improve the skills, strategy and performance of the healthcare team
Educate patients
Other
If Other
Because you are likely to make changes to your practice behaviors, you are eligible to qualify for T2P (Translation to Practice) Credit, an additional 2.0 Credits. Please provide your email address below and we will send you a link to a followup survey in six weeks. If you have made changes to your practice behaviors, you will receive those additional two credits.
[ Invalid e-mail address ]
What barriers to change do you foresee?
[ Required ]
Cost
Insurance Coverage
Formulary
Patient Compliance
Time with Patient
Other
If Other
What was your level of knowledge on this subject?
Before the presentation
[ Required ]
Select...
None
Little
Some
Considerable
Expert
After the presentation
[ Required ]
Select...
None
Little
Some
Considerable
Expert
The following patients all present with complaints of menopause-related VMS. For which patient would you recommend pharmacologic treatment with hormone therapy?
[ Required ]
A 62-year-old woman who has moderate VMS and says that she is afraid of getting a blood clot from taking hormones.
A 69-year-old woman who has a recurrence of VMS; when she took estrogen in the past, it was the only thing that helped with her symptoms. She has hypertension, hyperlipidemia, and diabetes.
A 51-year-old woman with a history of breast cancer, taking tamoxifen. She fears weight gain and sexual side effects from drugs but wants to try something for VMS.
A 54-year-old woman with severe menopausal VMS, hypothyroidism, and no history of cancer or thromboembolism.
Which statement is correct about novel neurokinin 3 receptor (NK3R) antagonists for treatment of menopause-associated VMS?
[ Required ]
In late-stage clinical trials, NK3R antagonists have demonstrated superiority over hormone therapy for reduction in VMS frequency and severity
NK3R antagonists are thought to reduce VMS by altering stimulation of neurons in the hypothalamic thermoregulatory center
NK3R antagonists are contraindicated in women who have severe VMS
There are currently 3 FDA-approved NK3R antagonists available in the United States
How confident do you feel in your answer to the previous question?
[ Required ]
Select...
Very confident
Confident
Somewhat confident
Not confident
What would you like to learn more about on this subject?
Submit